This is something I have considered, but it would be best to have RC220 bedded down before green-lighting something like this. Another factor to consider is if it would be better to get another organisation to do an update so that we get a second opinion.
Having said all this the only major thing that has changed is VO2Peak which makes accelerated approval for cardioprotection a possibility which further increases the value of bisantrene. Does anyone think that the problem with the current value of RAC is due to the scale of opportunity not being large enough?
General Comments / Chat, page-10124
-
- There are more pages in this discussion • 1,179 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
